Zebrafish Medulloblastoma Models

Background Models Details Phenotypic Evaluation Key Applications Study Examples

Background

Medulloblastoma is a highly malignant embryonal brain tumor that arises in the cerebellum and represents one of the most common malignant central nervous system tumors in children. It is classified into major molecular subgroups, including WNT, SHH, Group 3, and Group 4, each with distinct developmental origins, genetic drivers, metastatic risk, and clinical outcome. Key pathological features include rapid proliferation of undifferentiated tumor cells, cerebellar invasion, leptomeningeal dissemination, and, in some cases, MYC/MYCN amplification or aberrant SHH pathway activation. Patients commonly present with headache, vomiting, ataxia, abnormal gait, cranial nerve deficits, and symptoms of increased intracranial pressure.

Current treatment typically includes maximal safe surgical resection, craniospinal irradiation, and multi-agent chemotherapy. Molecular risk stratification has improved clinical management, and targeted strategies against SHH signaling, MYC-associated pathways, DNA damage response, and apoptotic vulnerabilities are under investigation. However, treatment remains limited by tumor heterogeneity, metastatic recurrence, therapy resistance, and long-term neurocognitive and endocrine toxicity in pediatric patients. Zebrafish medulloblastoma models provide a rapid vertebrate platform for studying subgroup-specific tumor biology, orthotopic tumor growth, dissemination, and early in vivo drug response.

Why Zebrafish?

Transparent larvae enable live imaging of brain tumor growth and dissemination.
Orthotopic implantation supports brain-relevant tumor behavior analysis.
Small size allows rapid drug efficacy and toxicity assessment.
Genetic tools enable modeling of SHH- and MYC-associated disease mechanisms.

Available Zebrafish Disease Models

Validated zebrafish medulloblastoma models combine orthotopic xenograft and genetic approaches to investigate subgroup-specific tumor biology, intracranial growth, dissemination, and therapeutic response.

Model Name	Induction Method	Features
Orthotopic Medulloblastoma Xenograft Model	Fluorescently labeled human medulloblastoma cell lines or patient-derived cells are microinjected into the zebrafish larval brain.	Suitable for rapid assessment of intracranial tumor growth, tumor burden, survival, and drug response. Particularly useful for early in vivo efficacy screening.
Medulloblastoma Cell Line Xenograft Model	Established medulloblastoma cell lines, such as DAOY, D283, D341, D425, or HD-MB03, are labeled and transplanted into zebrafish embryos or larvae.	A practical model for evaluating proliferation, invasion, dissemination, and compound activity across molecularly distinct medulloblastoma backgrounds.
SHH Medulloblastoma Genetic Model	SHH pathway activation is induced in zebrafish neural progenitor or cerebellar-lineage contexts using transgenic or somatic expression systems.	Supports studies of SHH-driven tumor initiation, pathway dependency, and targeted therapy response in a scalable vertebrate system.
Medulloblastoma-like PNET Somatic Gene Inactivation Model	Tumor suppressor genes are disrupted by somatic genome editing approaches, such as TALEN-mediated inactivation, to induce medulloblastoma-like primitive neuroectodermal tumors.	Useful for mechanism studies involving tumor suppressor loss, embryonal brain tumor formation, and genetic driver validation.

Phenotypic Evaluation & Validation Assays

Drug Response and Safety

Reduction in tumor burden
Inhibition of dissemination
Larval survival and gross morphology
Basic toxicity readouts, including edema and developmental delay

Tumor Biology

Proliferation and apoptosis changes
SHH, MYC/MYCN, or subgroup-associated marker expression
Neural progenitor or differentiation marker changes

Tumor Growth

Tumor fluorescence area or intensity
Intracranial tumor expansion
Tumor growth inhibition after treatment

Invasion and Dissemination

Migration distance from implantation site
Number of disseminated tumor foci
Brain or spinal-axis spread pattern

Key Applications

Rapid in vivo medulloblastoma drug screening for targeted agents, cytotoxic compounds, and combination therapies.
Orthotopic brain tumor growth studies using live fluorescence imaging in zebrafish larvae.
Subgroup-relevant mechanism studies, including SHH-driven and MYC/MYCN-associated medulloblastoma biology.
Evaluation of anti-invasive or anti-dissemination strategies for metastatic medulloblastoma research.
Early efficacy and tolerability assessment to support pediatric brain tumor drug development.

Study Examples

This study developed an orthotopic zebrafish medulloblastoma xenograft model for rapid in vivo drug testing. Medulloblastoma cells were implanted into the zebrafish brain, allowing tumor growth to be monitored by imaging-based readouts.

Fig. 1. Orthotopic implantation of medulloblastoma cells enables rapid assessment of intracranial tumor growth in zebrafish larvae (van Bree N, Oppelt AS, et al., 2025).

The authors established a scalable zebrafish model of Sonic hedgehog medulloblastoma by activating SHH pathway signaling in a zebrafish neural tumor context. The model was designed to support efficient tumor induction and analysis of SHH-driven medulloblastoma biology. Tumor formation, pathway activity, and pharmacological response were evaluated in vivo.

Fig. 2. Activation of SHH pathway signaling induces medulloblastoma-like tumor formation in zebrafish (Casey MJ, Chan PP, et al. 2024).

Accelerate Medulloblastoma Research with Zebrafish Models

Advance medulloblastoma research with zebrafish models designed for orthotopic tumor growth analysis, subgroup-relevant mechanism studies, dissemination assessment, and rapid in vivo drug testing.

Contact Our Scientists

References

van Bree N, Oppelt AS, et al. Development of an orthotopic medulloblastoma zebrafish model for rapid drug testing. Neuro-Oncology. 2025;27(3):779–794.
Casey MJ, Chan PP, et al. A simple and scalable zebrafish model of Sonic hedgehog medulloblastoma. Cell Reports. 2024;43(8):114559.

For research use only. Not intended for any clinical use.